Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IFRXNASDAQ:PRTANASDAQ:PRTCNASDAQ:ZVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIFRXInflaRx$0.80+0.9%$1.25$0.71▼$2.82$53.24M1.29287,222 shs131,633 shsPRTAProthena$6.07+0.2%$6.91$4.32▼$25.42$326.19M-0.08766,748 shs1.62 million shsPRTCPureTech Health$17.80+1.7%$17.75$13.30▼$26.79$420.33M1.154,714 shs9,305 shsZVRAZevra Therapeutics$9.15+1.7%$8.28$4.20▼$9.76$492.12M2.01672,277 shs316,726 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIFRXInflaRx-0.28%+1.67%-57.14%-40.38%-48.51%PRTAProthena+5.94%+7.07%-7.90%-52.09%-71.79%PRTCPureTech Health-3.62%-9.71%-3.52%-4.20%-38.15%ZVRAZevra Therapeutics-0.44%-1.42%+4.05%+10.43%+106.42%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIFRXInflaRx2.7543 of 5 stars3.53.00.00.02.61.70.6PRTAProthena3.6363 of 5 stars4.24.00.00.01.91.71.3PRTCPureTech Health1.8189 of 5 stars3.83.00.00.00.00.00.0ZVRAZevra Therapeutics2.7729 of 5 stars3.62.00.00.03.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIFRXInflaRx 3.00Buy$6.60725.00% UpsidePRTAProthena 2.33Hold$31.50418.95% UpsidePRTCPureTech Health 3.50Strong Buy$45.00152.81% UpsideZVRAZevra Therapeutics 3.11Buy$22.29143.56% UpsideCurrent Analyst Ratings BreakdownLatest IFRX, ZVRA, PRTA, and PRTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/20/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/29/2025IFRXInflaRxRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$2.005/29/2025IFRXInflaRxOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$6.00 ➝ $3.005/28/2025PRTAProthenaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform5/27/2025PRTAProthenaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$110.00 ➝ $81.005/27/2025PRTAProthenaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$78.00 ➝ $29.005/27/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral5/27/2025PRTAProthenaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$6.005/27/2025PRTAProthenaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/27/2025PRTAProthenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $14.005/27/2025PRTAProthenaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $18.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIFRXInflaRx$180K298.36N/AN/A$1.13 per share0.71PRTAProthena$135.16M2.42N/AN/A$9.05 per share0.67PRTCPureTech Health$4.83M88.52$2.43 per share7.34$17.04 per share1.04ZVRAZevra Therapeutics$23.61M21.19N/AN/A$0.74 per share12.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIFRXInflaRx-$49.85M-$0.82N/AN/AN/A-33,362.70%-64.17%-53.39%8/6/2025 (Estimated)PRTAProthena-$122.31M-$2.08N/AN/AN/A-79.94%-21.61%-19.32%8/6/2025 (Estimated)PRTCPureTech Health$27.78MN/A0.00N/AN/AN/AN/AN/A7/30/2025 (Estimated)ZVRAZevra Therapeutics-$105.51M-$1.90N/A45.75N/A-226.78%-201.05%-53.55%8/12/2025 (Estimated)Latest IFRX, ZVRA, PRTA, and PRTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ZVRAZevra Therapeutics-$0.21-$0.06+$0.15-$0.06$16.96 million$20.40 million5/8/2025Q1 2025PRTAProthena-$0.92-$1.12-$0.20-$1.12$8.18 million$2.83 million5/7/2025Q1 2025IFRXInflaRx-$0.18-$0.14+$0.04-$0.14$0.03 million$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIFRXInflaRxN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/APRTCPureTech HealthN/AN/AN/AN/AN/AZVRAZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIFRXInflaRxN/A5.284.86PRTAProthenaN/A9.009.00PRTCPureTech HealthN/A9.339.33ZVRAZevra Therapeutics1.463.022.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIFRXInflaRx42.39%PRTAProthena97.08%PRTCPureTech Health0.04%ZVRAZevra Therapeutics35.03%Insider OwnershipCompanyInsider OwnershipIFRXInflaRx16.30%PRTAProthena9.20%PRTCPureTech Health5.30%ZVRAZevra Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIFRXInflaRx6067.13 million56.19 millionOptionablePRTAProthena13053.83 million48.88 millionOptionablePRTCPureTech Health10024.02 million22.75 millionNot OptionableZVRAZevra Therapeutics2054.68 million53.37 millionOptionableIFRX, ZVRA, PRTA, and PRTC HeadlinesRecent News About These CompaniesBrokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Target Price at $22.29June 23 at 1:14 AM | americanbankingnews.comCarret Asset Management LLC Buys Shares of 36,140 Zevra Therapeutics, Inc. (NASDAQ:ZVRA)June 21 at 5:22 AM | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Buy" by AnalystsJune 20, 2025 | marketbeat.comCantor Fitzgerald Predicts ZVRA FY2026 EarningsJune 11, 2025 | marketbeat.comBank of America Corp DE Increases Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)June 9, 2025 | marketbeat.comNuveen Asset Management LLC Reduces Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)June 5, 2025 | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Purchased by Millennium Management LLCJune 3, 2025 | marketbeat.comZevra Therapeutics: Zevra Announces Final Results of 2025 Annual Meeting of StockholdersMay 31, 2025 | finanznachrichten.deZevra Therapeutics Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to Board of Directors Amid Commitment to Growth StrategyMay 31, 2025 | nasdaq.comZevra Announces Final Results of 2025 Annual Meeting of StockholdersMay 29, 2025 | globenewswire.comCitizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PTMay 27, 2025 | insidermonkey.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of "Buy" by AnalystsMay 27, 2025 | marketbeat.comNorthern Trust Corp Buys 81,252 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)May 25, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Upgraded to Buy at Wall Street ZenMay 24, 2025 | marketbeat.comAll Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director NomineesMay 21, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Flora Growth (FLGC), Cardinal Health (CAH) and Zevra Therapeutics (ZVRA)May 16, 2025 | theglobeandmail.comWith 49% stake, Zevra Therapeutics, Inc. (NASDAQ:ZVRA) seems to have captured institutional investors' interestMay 15, 2025 | finance.yahoo.comZevra Reports First Quarter 2025 Financial Results and Corporate UpdateMay 14, 2025 | taiwannews.com.twZevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comZevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue EstimatesMay 13, 2025 | zacks.comZevra Therapeutics, Inc. Q1 2025 Earnings PreviewMay 12, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIFRX, ZVRA, PRTA, and PRTC Company DescriptionsInflaRx NASDAQ:IFRX$0.80 +0.01 (+0.88%) Closing price 04:00 PM EasternExtended Trading$0.82 +0.02 (+2.12%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.Prothena NASDAQ:PRTA$6.07 +0.01 (+0.17%) Closing price 04:00 PM EasternExtended Trading$6.15 +0.08 (+1.30%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.PureTech Health NASDAQ:PRTC$17.50 +0.00 (+0.03%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Zevra Therapeutics NASDAQ:ZVRA$9.15 +0.15 (+1.67%) Closing price 04:00 PM EasternExtended Trading$9.14 -0.01 (-0.05%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
